Interferon-induced depression: Strategies in treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 29, Issue 5, 2005, Pages 808-818

  Asnis, Gregory M ^a   De La Garza II, Richard ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressant; Depression; Interferon; Serotonin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ALPHA INTERFERON; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE RECEPTOR AFFECTING AGENT; DULOXETINE; ERYTHROPOIETIN; FLUOXETINE; HYPNOTIC AGENT; IMIPRAMINE; INTERFERON; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PSYCHOSTIMULANT AGENT; RIBAVIRIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM;

ANEMIA; ANHEDONIA; ANOREXIA; ARTHRALGIA; BIPOLAR DISORDER; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HYPOMANIA; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; PAIN; PROPHYLAXIS; RETINA HEMORRHAGE; RETINOPATHY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN BRUISING; SUICIDAL BEHAVIOR; THROMBOCYTOPENIA; THYROID DISEASE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIDEPRESSIVE AGENTS; ANTIVIRAL AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; HUMANS; INTERFERONS;

EID: 21244453638     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.03.006     Document Type: Review

References (97)

1. A.P. Aldenkamp, M. De Krom, and R. Reijs Newer antiepileptic drugs and cognitive issues Epilepsia 44 Suppl. 4 2003 21 29
2. American Psychiatric Association Practice guidelines for major depressive disorder in adults Am. J. Psychiatry 150 Suppl. 4 1993 1 51
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR Fourth Revised edition 2000 American Psychiatric Association Washington, DC
4. G.M. Asnis, S. Wetzler, W.C. Sanderson, R.S. Kahn, and H.M. van Praag Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects Psychiatry Res. 43 1992 65 76
5. G.M. Asnis, A. Chakraburtty, E.A. DuBoff, A. Krystal, P.D. Londborg, R. Rosenberg, B. Roth-Schechter, M.B. Scharf, and J.K. Walsh Zolpidem for persistent insomnia in SSRI-treated depressed patients J. Clin. Psychiatry 60 1999 668 676
6. G.M. Asnis, R. De la Garza II., S.R. Kohn, J.F. Reinus, M. Henderson, and J. Shah IFN-induced depression: a role for NSAIDs Psychopharmacol. Bull. 37 2003 29 50
7. G.M. Asnis, R. De La Garza II, A.H. Miller, and C.L. Raison Ribavirin may be an important factor in IFN-induced neuropsychiatric effects J. Clin. Psychiatry 65 2004 581
8. G.M. Asnis, R. De La Garza II, S.A. Rego, M.A. Henderson, and J.F. Reinus Interferon for hepatitis C patients with psychiatric disorders Am. J. Psychiatry 161 2004 2332
9. L.M. Bang, and G.M. Keating Paroxetine controlled release CNS Drugs 18 2004 355 364
10. P. Baumann, and F. Larsen The pharmacokinetics of citalopram Rev. Contemp. Pharmacother. 6 1995 287 295
11. A.T. Beck, C.H. Ward, M. Mendelson, J. Mock, and J. Erbaugh An inventory for measuring depression Arch. Gen. Psychiatry 4 1961 561 571
12. S. Bonaccorso, V. Marino, M. Biondi, F. Grimaldi, F. Ippoliti, and M. Maes Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus J. Affect. Disord. 72 2002 237 241
13. S. Bonaccorso, V. Marino, A. Puzella, M. Pasquini, M. Biondi, M. Artini, C. Almerighi, R. Verkerk, H. Meltzer, and M. Maes Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system J. Clin. Psychopharmacol. 22 2002 86 90
14. C.L. Bowden, G.M. Asnis, L.D. Ginsberg, B. Bentley, R. Leadbetter, and R. White Safety and tolerability of lamotrigine for bipolar disorder Drug Safety 7 2004 173 184
15. O. Brawman-Mintzer, and K.A. Yonkers New trends in the treatment of anxiety disorders CNS Spectr. 9 8 Suppl. 7 2004 19 27
16. S. Caccia Metabolism of the newest antidepressants: comparisons with related predecessors IDrugs 7 2004 143 150
17. J.R. Calabrese, C.L. Bowden, G.S. Sachs, J.A. Ascher, E. Monaghan, and G.D. Rudd A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group J. Clin. Psychiatry 60 1999 79 88
18. J.R. Calabrese, C.L. Bowden, G. Sachs, L.N. Yatham, K. Behnke, O.P. Mehtonen, P. Montgomery, J. Ascher, W. Paska, N. Earl, and J. DeVeaugh-Geiss Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder J. Clin. Psychiatry 64 2003 1013 1024
19. L. Capuron, and A. Ravaud Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state N. Engl. J. Med. 340 1999 1370
20. L. Capuron, J.F. Gumnick, D.L. Musselman, D.H. Lawson, A. Reemsnyder, C.B. Nemeroff, and A.H. Miller Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions Neuropsychopharmacology 26 2002 643 652
21. A.H. Clayton, J.K. Warnock, S.G. Kornstein, R. Pinkerton, A. Sheldon-Keller, and E.L. McGarvey A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction J. Clin. Psychiatry 65 2004 62 67
22. A. Coppen, M.T. Abou-Saleh, P. Milln, J. Bailey, M. Metcalfe, B.H. Burns, and A. Armond Lithium continuation therapy following electroconvulsive therapy Br. J. Psychiatry 139 1981 284 287
23. C.C. Crone, G.M. Gabriel, and T.N. Wise Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C Clevel. Clin. J. Med. 71 Suppl. 3 2004 S27 S32
24. J.J. Cush Safety overview of new disease-modifying antirheumatic drugs Rheum. Dis. Clin. North Am. 30 2004 237 255
25. O. Dalgard, K. Bjoro, K. Hellum, B. Myrvang, T. Bjoro, E. Haug, and H. Bell Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy J. Intern. Med. 251 2002 400 406
26. S.O. Dalton, C. Johansen, L. Mellemkjaer, B. Norgard, H.T. Sorensen, and J.H. Olsen Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study Arch. Intern. Med. 163 2003 59 64
27. J.C. de Jong, P.B. van den Berg, H. Tobi, and LT. de Jong-van den Berg Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects Br. J. Clin. Pharmacol. 55 2003 591 595
28. R. De La Garza II, and G.M. Asnis The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus Brain Res. 977 2003 70 79
29. R. De La Garza II, K.R. Fabrizio, G.E. Radoi, T. Vlad, and G.M. Asnis The non-steroidal anti-inflammatory drug diclofenac sodium attenuates lipopolysaccharide-induced alterations to reward behavior and corticosterone release Behav. Brain Res. 149 2004 77 85
30. R. De La Garza II, G.M. Asnis, K.R. Fabrizio, and E. Pedrosa Acute diclofenac treatment attenuates lipopolysaccharide-induced alterations to basic reward behavior and HPA axis activation in rats Psychopharmacology 179 2005 356 365
31. E. Dieperink, S.B. Ho, L. Tetrick, P. Thuras, K. Dua, and M.L. Willenbring Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C Gen. Hosp. Psych. 26 2004 237 240
32. C.M. Dording, D. Mischoulon, T.J. Petersen, R. Kornbluh, J. Gordon, A.A. Nierenberg, J.E. Rosenbaum, and M. Fava The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists Ann. Clin. Psychiatry 14 2002 143 147
33. C.B. Eap, G. Bertschy, K. Powell, and P. Baumann Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone J. Clin. Psychopharmacol. 17 1997 113 117
34. A. Farah Interferon-induced depression treated with citalopram J. Clin. Psychiatry 63 2002 166 167
35. M. Fava Depression with anger attacks J. Clin. Psychiatry 59 Suppl. 18 1998 18 22
36. B.L. Felker, K.L. Sloan, J.A. Dominitz, and R.F. Barnes The safety of valproic acid use for patients with hepatitis C infection Am. J. Psychiatry 160 2003 174 178
37. M. First, R. Spitzer, M. Gibbon, and J. Williams Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition (SCID-I?P, Version 2.0) 1995 New York State Psychiatric Institute New York, NY
38. E. Frank, D.J. Kupfer, J.M. Perel, C. Cornes, D.B. Jarrett, A.G. Mallinger, M.E. Thase, A.B. McEacran, and V.J. Grochocinski Three year outcome for maintenance therapies in recurrent depression Arch. Gen. Psychiatry 47 1990 1093 1099
39. M.W. Fried Side effects of therapy of hepatitis C and their management Hepatology 36 5 Suppl. 1 2002 S237 S244
40. M.W. Fried, and S.J. Hadziyannis Treatment of chronic hepatitis C infection with peginterferons plus ribavirin Semin. Liver Dis. 24 Suppl. 2 2004 47 54
41. A.J. Gelenberg, R.B. Lydiard, R.L. Rudolph, L. Aguiar, J.T. Haskins, and E. Salinas Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial JAMA 283 2000 3082 3088
42. S.N. Ghaemi, D.J. Hsu, F. Soldani, and F.K. Goodwin Antidepressants in bipolar disorder: the case for caution Bipolar Disord. 5 2003 421 433
43. O.C. Gleason, and W.R. Yates Five cases of interferon-alpha-induced depression treated with antidepressant therapy Psychosomatics 40 1999 510 512
44. O.C. Gleason, W.R. Yates, M.A. Philipsen, M.D. Isbell, and B.G. Pollock Plasma levels of citalopram in depressed patients with hepatitis C Psychosomatics 45 2004 29 33
45. L.S. Goldman Successful treatment of interferon alfa-induced mood disorder with nortriptyline Psychosomatics 35 1994 412 413
46. F.K. Goodwin, and S.N. Ghaemi Understanding manic-depressive illness Arch. Gen. Psychiatry 55 1998 23 25
47. T.R. Green Bupropion for SSRI-induced fatigue J. Clin. Psychiatry 58 1997 174
48. M.M. Gutierrez, J. Rosenberg, and W. Abramowitz An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir Clin. Ther. 25 2003 1200 1210
49. P. Hauser, R. Soler, S. Reed, R. Kane, M. Gulati, J. Khosla, M.A. Kling, A.D. Valentine, and C.A. Meyers Prophylactic treatment of depression induced by interferon-alpha Psychosomatics 41 2000 439 441
50. P. Hauser, J. Khosla, H. Aurora, J. Laurin, M.A. Kling, J. Hill, M. Gulati, A.J. Thornton, R.L. Schultz, A.D. Valentine, C.A. Meyers, and C.D. Howell A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C Mol. Psychiatry 7 2002 942 947
51. C. Hejny, P. Sternberg, D.H. Lawson, K. Greiner, and T.M.Jr. Aaberg Retinopathy associated with high-dose interferon alfa-2b therapy Am. J. Ophthalmol. 131 2001 782 787
52. N. Horikawa, T. Yamazaki, N. Izumi, and M. Uchihara Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study Gen. Hosp. Psych. 25 2003 34 38
53. I.M. Jackson The thyroid axis and depression Thyroid 8 1998 951 956
54. H. Janssen, J. Brouwer, R. van der Mast, and S. Schalm Suicide associated with alfa-interferon therapy for chronic viral hepatitis J. Hepatol. 21 1994 241 243
55. A. Khan, L.D. Ginsberg, G.M. Asnis, F.K. Goodwin, K.H. Davis, A.A. Krishnan, and B.E. Adams Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder J. Clin. Psychiatry 65 2004 1483 1490
56. M.R. Kraus, A. Schafer, H. Faller, H. Csef, and M. Scheurlen Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C Aliment. Pharmacol. Ther. 16 2002 1091 1099
57. J.L. Levenson, and H.J. Fallon Fluoxetine treatment of depression caused by interferon-alpha Am. J. Gastroenterol. 88 1993 760 761
58. R.S. Lott, K.M. Helmboldt, and K.J. Madaras-Kelly Retrospective evaluation of the effect of valproate therapy on transaminase elevations in patients with hepatitis C Pharmacotherapy 21 2001 1345 1351
59. I. Lucki, and O.F. O'Leary Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs J. Clin. Psychiatry 65 Suppl. 4 2004 11 24
60. M.E. Lynch Antidepressants as analgesics: a review of randomized controlled trials J. Psychiatry Neurosci. 26 2001 30 36
61. W.C. Maddrey Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients Semin. Liver Dis. 19 Suppl. 1 1999 67 75
62. M. Malaguarnera, I. Di Fazio, S. Restuccia, G. Pistone, L. Ferlito, and L. Rampello Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha Neuropsychobiology 37 1998 93 97
63. P. Malek-Ahmadi, and E. Ghandour Bupropion for treatment of interferon-induced depression Ann. Pharmacother. 38 2004 1202 1205
64. A.K. Malhotra, G.M. Murphy Jr., and J.L. Kennedy Pharmacogenetics of psychotropic drug response Am. J. Psychiatry 161 2004 780 796
65. U.R. Malik, D.F. Makower, and S. Wadler Interferon-mediated fatigue Cancer 92 6 Suppl. 2001 1664 1668
66. P.B. Mitchell, and G.S. Malhi Bipolar depression: phenomenological overview and clinical characteristics Bipolar Disord. 6 2004 530 539
67. D.L. Musselman, D.H. Lawson, J.F. Gumnick, A.K. Manatunga, S. Penna, R.S. Goodkin, K. Greiner, C.B. Nemeroff, and A.H. Miller Paroxetine for the prevention of depression induced by high-dose interferon alfa N. Engl. J. Med. 344 2001 961 966
68. T.B. Newman A black-box warning for antidepressants in children? N. Engl. J. Med. 351 2004 1595 1598
69. T. Otsubo, H. Miyaoka, K. Kamijima, M. Onuki, M. Ishii, and K. Mitamura Depression during interferon therapy in chronic hepatitis C patients-a prospective study Seishin. Shinkeigaku. Zasshi. 99 1997 101 127
70. J.R. Owen, and C.B. Nemeroff New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine Depress. Anxiety 7 Suppl. 1 1998 24 32
71. L.Y. Park-Wyllie, and T. Antoniou Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series AIDS 17 2003 638 640
72. M. Piazza, G. Tosone, G. Borgia, R. Orlando, G. Fenzi, M. Vitale, A. Bloise, A. Mariano, and V. Macchia Long-term interferon-alpha therapy does not affect sex hormones in males with chronic hepatitis C J. Interferon Cytokine Res. 17 1997 525 529
73. J.M. Piper, T.T. Wen, and E.M. Xenakis Interferon therapy in primary care Prim. Care Update Ob Gyns 8 2001 163 169
74. G.L. Plosker, and G.M. Keating Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis c virus and HIV co-infection Drugs 64 2004 2823 2843
75. S.H. Preskorn Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism Clin. Pharmacokinet. 32 Suppl. 1 1997 1 21
76. S.H. Preskorn Duloxetine J. Psychiatr. Pract. 10 2004 375 385
77. P.J. Pockros, M.L. Shiffman, E.R. Schiff, M.S. Sulkowski, Z. Younossi, D.T. Dieterich, T.L. Wright, S.H. Mody, K.L. Tang, B.L. Goon, P.J. Bowers, G. Leitz, and N.H. Afdhal PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
78. R.M. Post, G.S. Leverich, W.A. Nolen, R.W. Kupka, L.L. Altshuler, M.A. Frye, T. Suppes, S. McElroy, P. Keck, H. Grunze, and J. Walden Stanley foundation bipolar network. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network Bipolar Disord. 5 2003 396 406
79. C.L. Raison, S.D. Broadwell, A.S. Borisov, A.K. Manatunga, L. Capuron, B.J. Woolwine, I.M. Jacobson, C.B. Nemeroff, and A.H. Miller Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C Brain Behav. Immun. 19 2005 23 27
80. R. Ramasubbu Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders Acta Psychiatr. Scand. 104 2001 236 238
81. S. Russo, J.C. Boon, J. Korf, and E.B. Haagsma Mirtazapine for the treatment of interferon-induced psychopathology Gen. Hosp. Psych. 25 2003 497
82. U. Schiemann, and K. Hengst Thyroid echogenicity in manic-depressive patients receiving lithium therapy J. Affect. Disord. 70 2002 85 90
83. T.M. Schramm, B.R. Lawford, G.A. Macdonald, and W.G. Cooksley Sertraline treatment of interferon-alfa-induced depressive disorder Med. J. Aust. 173 2000 359 361
84. V.L. Serebruany, P.A. Gurbel, and C.M. O'Connor Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors Pharmacol. Res. 43 2001 453 462
85. P.H. Silverstone, and T. Silverstone A review of acute treatments for bipolar depression Int. Clin. Psychopharmacol. 19 2004 113 124
86. S.M. Stahl Essential Psychopharmacology: Neuroscientific Basis and Practical Applications 2nd ed. 2000 Cambridge University Press Cambridge United Kingdom
87. M.S. Sulkowski, R. Wasserman, L. Brooks, L. Ball, and R. Gish Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection J. Viral Hepatitis 11 2004 243 250
88. M. Tohen, J. Castillo, R.J. Baldessarini, C. Zarate Jr., and J.C. Kando Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk Am. J. Psychiatry 152 1995 413 418
89. P.C. Trask, P. Esper, M. Riba, and B. Redman Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions J. Clin. Oncol. 18 2000 2316 2326
90. K.S. Vesta, and P.J. Medina Valproic acid-induced neutropenia Ann. Pharmacother. 37 2003 819 821
91. L.K. Vainionpaa, K. Mikkonen, J. Rattya, M. Knip, A.J. Pakarinen, V.V. Myllyla, and J.I. Isojarvi Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication Epilepsia 45 2004 197 203
92. R.M. Weinrieb, M. Auriacombe, K.G. Lynch, K.M. Chang, and J.D. Lewis A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients J. Clin. Psychiatry 64 2003 1502 1510
93. M.M. Wohlreich, J.G. Watkin, and J.S. Gonzales Duloxetine's role in the treatment of depression and associated painful physical symptoms J. Clin. Psychiatry 65 2004 1018 1019
94. L.N. Yatham, J.R. Calabrese, and V. Kusumakar Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options Bipolar Disord. 5 2003 85 97
95. R. Yirmiya Endotoxin produces a depressive-like episode in rats Brain Res. 711 1996 163 174
96. D. Zdilar, K. Franco-Bronson, N. Buchler, J.A. Locala, and Z.M. Younossi Hepatitis C, interferon alfa, and depression Hepatology 31 2000 1207 1211
97. W.W.K. Zung, C.B. Richards, and M.J. Short Self-rating depression scale in an outpatient clinic Arch. Gen. Psychiatry 13 1965 508 515